Shares of companies involved in psychedelic-related therapies are surging in premarket trading Monday after President Donald Trump signed an executive order to expedite research and access.
Angel Adegbesan is a Business Reporter at various prominent publications. With a focus on cannabis and psychedelics, healthcare technology, and finance, Angel explores the intersections of digital health, telehealth, and psychedelic research. Their work has been featured in esteemed outlets including the Toronto Star, Financial Post, and The Washington Post.











